Alcon Inc. reported first‑quarter 2026 results that showed a 10% rise in net sales to $2.685 billion, up 6% on a constant‑currency basis from the same period a year earlier. Core diluted earnings per share climbed to $0.85, a 16% increase from $0.73 in Q1 2025, while operating income fell to $292 million from $468 million in the prior year, reflecting higher costs associated with new product launches and tariff impacts.
Revenue growth was driven by strong performance in the surgical and vision‑care segments. Surgical sales rose 10% to $1.5 billion, and vision‑care sales increased 9% to $1.2 billion. The company’s product launches—Unity VCS and CS surgical systems, PanOptix Pro intraocular lenses, Tryptyr dry‑eye therapy, and Precision7—contributed significantly to the top‑line expansion. However, revenue missed analyst consensus estimates of $2.71 billion by roughly $10 million, a shortfall that weighed on investor sentiment.
Operating income contracted by $176 million, largely due to $33 million in incremental tariff charges, costs associated with efficiency initiatives, and impairment charges. These headwinds offset the benefit of higher sales volume and improved operating leverage, resulting in a decline in reported operating income despite the EPS beat. The company’s core operating margin improved to 21.2% from 20.8% year‑over‑year, reflecting stronger pricing power in high‑margin segments.
The EPS beat was driven by disciplined cost management and a favorable mix shift toward higher‑margin products. Management raised its full‑year 2026 core EPS guidance to 10%–13% from 9%–12%, signaling confidence in continued earnings growth. The company also maintained its constant‑currency sales growth projection of 5%–7%, underscoring expectations of sustained demand for its new launches.
"2026 is off to a solid start, driven by strong performance from our new product launches, including Unity VCS and CS, PanOptix Pro, Tryptyr and Precision7. Combined with the resilience of our balanced portfolio, we are well positioned to navigate market variability and maintain consistent performance," said CEO David J. Endicott. CFO Tim Stonescipher added, "Our first quarter sales of $2.7 billion were up 6% versus prior year in our surgical franchise. Revenue was up 6% year over year to $1.5 billion."
Investors reacted negatively to the results, citing the revenue miss and the sharp decline in operating income as primary concerns, even as the EPS beat and guidance upgrade suggested underlying strength and management confidence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.